Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires its Dynamic Redistribution during Immunological Synapse Formation

Molecular and Cellular Biology

Volumn 23, Issue 22, 2003, Pages 8042-8057

  Arp, Jacqueline ^a,b   Kirchhof, Mark G ^a,b   Baroja, Miren L ^a,b   Nazarian, Steven H ^a,b   Chau, Thu A ^a,b   Strathdee, Craig A ^a,c   Ball, Eric H ^b   Madrenas, Joaquín ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE 4B2; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIPID MEMBRANE; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIGNAL TRANSDUCTION; SYNAPSE; T LYMPHOCYTE ACTIVATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CELL COMPARTMENTATION; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MEMBRANE MICRODOMAINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0242664138     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.22.8042-8057.2003     Document Type: Article

References (57)

1. Aandahl, E. M., W. J. Moretto, P. A. Haslett, T. Vang, T. Bryn, K. Tasken, and D. F. Nixon. 2002. Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type 1. J. Immunol. 169:802-808.
2. Allenspach, E. J., P. Cullinan, J. Tong, Q. Tang, A. G. Tesciuba, J. L. Cannon, S. M. Takahashi, R. Morgan, J. K. Burkhardt, and A. I. Sperling. 2001. ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. Immunity 15:739-750.
3. Baroja, M. L., L. B. Cieslinski, T. J. Torphy, R. L. Wange, and J. Madrenas. 1999. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J. Immunol. 162:2016-2023.
4. Beard, M. B., A. E. Olsen, R. E. Jones, S. Erdogan, M. D. Houslay, and G. B. Bolger. 2000. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J. Biol. Chem. 275:10349-10358.
5. Bielekova, B., A. Lincoln, H. McFarland, and R. Martin. 2000. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 164:1117-1124.
6. Bloom, T. J., and J. A. Beavo. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93:14188-14192.
7. Burns, F., A. Z. Zhao, and J. A. Beavo. 1996. Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications. Adv. Pharmacol. 36:29-48.
8. Butman, B. T., T. Jacobsen, O. G. Cabatu, and L. Y. Bourguignon. 1981. The involvement of cAMP in lymphocyte capping. Cell. Immunol. 61:397-403.
9. Chau, L. A., J. A. Bluestone, and J. Madrenas. 1998. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J. Exp. Med. 187:1699-1709.
10. Cherukuri, A., M. Dykstra, and S. K. Pierce. 2001. Floating the raft hypothesis: lipid rafts play a role in immune cell activation. Immunity 14:657-660.
11. Conti, M., and S. L. Jin. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63:1-38.
12. Costello, P. S., M. Gallagher, and D. A. Cantrell. 2002. Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse. Nat. Immunol. 3:1082-1089.
13. Darlington, P. J., M. L. Baroja, T. A. Chau, E. Siu, V. Ling, B. M. Carreno, and J. Madrenas. 2002. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J. Exp. Med. 195:1337-1347.
14. Delon, J., K. Kaibuchi, and R. N. Germain. 2001. Exclusion of CD43 from the immunological synapse is mediated by phosphorylation-regulated relocation of the cytoskeletal adaptor moesin. Immunity 15:691-701.
15. Delon, J., S. Stoll, and R. N. Germain. 2002. Imaging of T-cell interactions with antigen presenting cells in culture and in intact lymphoid tissue. Immunol. Rev. 189:51-63.
16. Erdogan, S., and M. D. Houslay. 1997. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem. J. 321:165-175.
17. Francis, S. H., I. V. Turko, and J. D. Corbin. 2001. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65:1-52.
18. Giembycz, M. A., C. J. Corrigan, J. Seybold, R. Newton, and P. J. Barnes. 1996. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118:1945-1958.
19. Glavas, N. A., C. Ostenson, J. B. Schaefer, V. Vasta, and J. A. Beavo. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc. Natl. Acad. Sci. USA 98:6319-6324.
20. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 1999. The immunological synapse: a molecular machine controlling T cell activation. Science 285:221-227.
21. Houslay, M. D., and D. R. Adams. 2003. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370:1-18.
22. Houslay, M. D., M. Sullivan, and G. B. Bolger. 1998. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44:225-342.
23. Kammer, G. M., C. A. Boehm, S. A. Rudolph, and L. A. Schultz. 1988. Mobility of the human T lymphocyte surface molecules CD3, CD4, and CD8: regulation by a cAMP-dependent pathway. Proc. Natl. Acad. Sci. USA 85:792-796.
24. Kenan, Y., T. Murata, Y. Shakur, E. Degerman, and V. C. Manganiello. 2000. Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J. Biol. Chem. 275:12331-12338.
25. Kovala, T., B. D. Sanwal, and E. H. Ball. 1997. Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants. Biochemistry 36:2968-2976.
26. Ledbetter, J. A., M. Parsons, P. J. Martin, J. A. Hansen, P. S. Rabinovitch, and C. H. June. 1986. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J. Immunol. 137:3299-3305.
27. Lerner, A., D. H. Kim, and R. Lee. 2000. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk. Lymphoma 37:39-51.
28. Li, L., C. Yee, and J. A. Beavo. 1999. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283:848-851.
29. Manganiello, V. C., and E. Degerman. 1999. Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb. Haemost. 82:407-411.
30. McLaughlin, M. M., L. B. Cieslinski, M. Burman, T. J. Torphy, and G. P. Livi. 1993. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J. Biol. Chem. 268:6470-6476.
31. McPhee, I., L. Pooley, M. Lobban, G. Bolger, and M. D. Houslay. 1995. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310:965-974.
32. Michle, A. M., G. Rena, M. M. Harnett, and M. D. Houslay. 1998. Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases. Cell Biochem. Biophys. 28:161-185.
33. Monks, C. R., B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. 1998. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82-86.
34. Moon, E. Y., and A. Lerner. 2003. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 101:4122-4130.
35. Morgan, M. M., C. M. Labno, G. A. Van Seventer, M. F. Denny, D. B. Straus, and J. K. Burkhardt. 2001. Superantigen-induced T cell:B cell conjugation is mediated by LFA-1 and requires signaling through Lck, but not ZAP-70. J. Immunol. 167:5708-5718.
36. Ogawa, R., M. B. Streiff, A. Bugayenko, and G. J. Kato. 2002. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 99:3390-3397.
37. Park, D. J., H. K. Min, and S. G. Rhee. 1992. Inhibition of CD3-linked phospholipase C by phorbol ester and by cAMP is associated with decreased phosphotyrosine and increased phosphoserine contents of PLC-gamma 1. J. Biol. Chem. 267:1496-1501.
38. Perry, S. J., G. S. Baillie, T. A. Kohout, I. McPhee, M. M. Magiera, K. L. Ang, W. E. Miller, A. J. McLean, M. Conti, M. D. Houslay, and R. J. Lefkowitz. 2002. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298:834-836.
39. Robicsek, S. A., D. K. Blanchard, J. Y. Djeu, J. J. Krzanowski, A. Szentivanyi, and J. B. Polson. 1991. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42:869-877.
40. Roumier, A., J. C. Olivo-Marin, M. Arpin, F. Michel, M. Martin, P. Mangeat, O. Acuto, A. Dautry-Varsat, and A. Alcover. 2001. The membrane-microfilament linker ezrin is involved in the formation of the immunological synapse and in T cell activation. Immunity 15:715-728.
41. Schmitt, J. M., and P. J. Stork. 2002. PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rapl. Mol. Cell 9:85-94.
42. Seybold, J., R. Newton, L. Wright, P. A. Finney, N. Suttorp, P. J. Barnes, I. M. Adcock, and M. A. Giembycz. 1998. Induction of phosphodiesterases 3B, 4A4, 4D1, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization. J. Biol. Chem. 273:20575-20588.
43. Shakur, Y., K. Takeda, Y. Kenan, Z. X. Yu, G. Rena, D. Brandt, M. D. Houslay, E. Degerman, V. J. Ferrans, and V. C. Manganiello. 2000. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J. Biol. Chem. 275:38749-38761.
44. Shakur, Y., M. Wilson, L. Pooley, M. Lobban, S. L. Griffiths, A. M. Campbell, J. Beattie, C. Daly, and M. D. Houslay. 1995. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J. 306:801-809.
45. Shaw, A. S. 2001. FERMing up the synapse. Immunity 15:683-686.
46. Skalhegg, B. S., and K. Tasken. 2000. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front. Biosci. 5:D678-D693.
47. Strathdee, C. A., M. R. McLeod, and J. R. Hall. 1999. Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene 229:21-29.
48. Sun, Y., L. Li, F. Lau, J. A. Beavo, and E. A. Clark. 2000. Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4. J. Immunol. 165:1755-1761.
49. Tenor, H., L. Staniciu, C. Schudt, A. Hatzelmann, A. Wendel, R. Djukanovic, M. K. Church, and J. K. Shute. 1995. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin. Exp. Allergy 25:616-624.
50. Thompson, W. J., C. P. Ross, W. J. Pledger, S. J. Strada, R. L. Banner, and E. M. Hersh. 1976. Cyclic adenosine 3′:5′-monophosphate phosphodiesterase. Distinct forms in human lymphocytes and monocytes. J. Biol. Chem. 251:4922-4929.
51. Tomas, E. M., T. A. Chau, and J. Madrenas. 2002. Clustering of a lipid-raft associated pool of ERM proteins at the immunological synapse upon T cell receptor or CD28 ligation. Immunol. Lett. 83:143-147.
52. Torphy, T. J., and C. Page. 2000. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol. Sci. 21:157-159.
53. van der Merwe, P. A., S. J. Davis, A. S. Shaw, and M. L. Dustin. 2000. Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin. Immunol. 12:5-21.
54. Vang, T., K. M. Torgersen, V. Sundvold, M. Saxena, F. O. Levy, B. S. Skalhegg, V. Hansson, T. Mustelin, and K. Tasken. 2001. Activation of the COOH-terminal Src kinase (Csk) bv cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J. Exp. Med. 193:497-507.
55. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283:680-682.
56. Xu, R. X., A. M. Hassell, D. Vanderwall, M. H. Lambert, W. D. Holmes, M. A. Luther, W. J. Rocque, M. V. Milburn, Y. Zhao, H. Ke, and R. T. Nolte. 2000. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288:1822-1825.
57. Zaccolo, M., and T. Pozzan. 2002. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295:1711-1715.